EA202090315A1 - PHARMACEUTICAL COMPOSITION CONTAINING ALIMEMAZINE TARTRATE - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING ALIMEMAZINE TARTRATE

Info

Publication number
EA202090315A1
EA202090315A1 EA202090315A EA202090315A EA202090315A1 EA 202090315 A1 EA202090315 A1 EA 202090315A1 EA 202090315 A EA202090315 A EA 202090315A EA 202090315 A EA202090315 A EA 202090315A EA 202090315 A1 EA202090315 A1 EA 202090315A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition containing
pharmaceutical composition
alimemazine tartrate
relates
auxiliary components
Prior art date
Application number
EA202090315A
Other languages
Russian (ru)
Other versions
EA039058B1 (en
Inventor
Кирилл Константинович Сыров
Владимир Викторович НЕСТЕРУК
Original Assignee
Общество С Ограниченной Ответственностью "Валента-Интеллект"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Валента-Интеллект" filed Critical Общество С Ограниченной Ответственностью "Валента-Интеллект"
Publication of EA202090315A1 publication Critical patent/EA202090315A1/en
Publication of EA039058B1 publication Critical patent/EA039058B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds

Abstract

Изобретение относится к области химико-фармацевтической промышленности и медицины и касается способов получения новых препаративных форм нейролептиков. Фармацевтический состав, содержащий алимемазина тартрат и вспомогательные компоненты, отличается тем, что в качестве вспомогательных компонентов выбраны микрокристаллическая целлюлоза, гипромеллоза, кремния диоксид коллоидный и стеарат магния.The invention relates to the field of chemical-pharmaceutical industry and medicine, and relates to methods for producing new formulations of antipsychotics. The pharmaceutical composition containing alimemazine tartrate and auxiliary components differs in that microcrystalline cellulose, hypromellose, colloidal silicon dioxide and magnesium stearate are selected as auxiliary components.

EA202090315A 2017-07-24 2018-07-16 Pharmaceutical composition containing alimemazine tartrate EA039058B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017126475A RU2659200C1 (en) 2017-07-24 2017-07-24 Pharmaceutical composition containing alimamazine tartrate
PCT/RU2018/000466 WO2019022639A1 (en) 2017-07-24 2018-07-16 Pharmaceutical composition containing alimemazine tartrate

Publications (2)

Publication Number Publication Date
EA202090315A1 true EA202090315A1 (en) 2020-05-12
EA039058B1 EA039058B1 (en) 2021-11-26

Family

ID=62816017

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090315A EA039058B1 (en) 2017-07-24 2018-07-16 Pharmaceutical composition containing alimemazine tartrate

Country Status (3)

Country Link
EA (1) EA039058B1 (en)
RU (1) RU2659200C1 (en)
WO (1) WO2019022639A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240050442A1 (en) * 2020-12-07 2024-02-15 Centre National De La Recherche Scientifique Trimeprazine derivatives and compositions comprising the same for treating a neuropsychiatric disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5218M (en) * 1965-06-18 1967-07-03
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
RU2007104969A (en) * 2007-02-09 2008-08-20 Маргарита Алексеевна Морозова (RU) METHOD FOR TREATING MIGRAINE AND APPLICATION OF ALIMEMASINE TARTRATE FOR TREATMENT OF MIGRAINE
RU2384336C1 (en) * 2009-04-22 2010-03-20 Маргарита Алексеевна Морозова Pharmaceutical composition for correction of psychosomatic manifestations
RU2424807C2 (en) * 2009-08-31 2011-07-27 Маргарита Алексеевна Морозова Pharmaceutical composition of prolonged action for correction of psychosomatic manifestations

Also Published As

Publication number Publication date
EA039058B1 (en) 2021-11-26
RU2659200C1 (en) 2018-06-28
WO2019022639A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CY1124548T1 (en) MONO-OR DISUBTITUTED INDOLE DERIVATIVES AS DANGE VIRUS REPLICATION INHIBITORS
EA201892395A1 (en) DRUG COMPOSITIONS OF LSD1 INHIBITOR
PH12017500571A1 (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017500503A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
PH12018500569A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EA201692007A1 (en) IZOINDOLINON COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA, AND RELATED DISORDERS
EA201891336A1 (en) Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
PH12017501272A1 (en) Indole derivatives as dengue viral replication inhibitors
JOP20160198B1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EA201991447A1 (en) VISCOSITY REDUCTION OF PHARMACEUTICAL COMPOSITIONS
EA202090683A2 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
EA201790650A1 (en) DOSAGE FORM AND METHODS OF APPLICATION OF ABIRATERONE ACETATE
EA201792487A1 (en) COMPOSITIONS OF HYDROXYPROPYL-BET-CYCLODEXTRINS AND METHODS
TR201821116A2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING POSACONAZOL AND THE MANUFACTURING METHOD
BR112017009510A2 (en) compositions comprising cyclosporine
EA201890944A1 (en) PHARMACEUTICAL COMPOSITIONS OF NILOTINIBA HYDROCHLORIDE
EA202090315A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ALIMEMAZINE TARTRATE
EA202090913A1 (en) COMPOSITION OF MODIFIED RELEASE TABLETS CONTAINING MIRABEGRON
EA202191515A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING APIXABAN
MX2017013879A (en) Compositions comprising anakinra.
EA201891680A1 (en) INDAN DERIVATIVES AS MGLUR7 MODULATORS
EA201990041A1 (en) COMPOSITIONS CONTAINING THYMOL, AND THEIR APPLICATION FOR THE TREATMENT OF ROSACEA FOR LOCAL APPLICATION
EA202090666A1 (en) APPLICATION OF BENZOATE-CONTAINING COMPOSITION FOR TREATMENT OF GLYCINE ENCEPHALOPATHY
BR112019006588A2 (en) immediate release pharmaceutical composition
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors